Previous 10 | Next 10 |
Co-Diagnostics (NASDAQ: CODX), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, today announced that its joint venture for manufacturing, CoSara Diagnostics Pvt Ltd, has obtained regulatory clearance for five tests to be manufa...
New York City, Dec. 03, 2019 (GLOBE NEWSWIRE) -- Co-Diagnostics, Inc. (Nasdaq: CODX) , a biotech company with a patented platform for the development of molecular diagnostic tests, released what could arguably be the most significant news in its history earlier today with the announcement ...
CoSara Saragene™ tests for tuberculosis, malaria, hepatitis B, hepatitis C, and human papillomavirus now available for sale and distribution as in vitro diagnostics Co-Diagnostics, Inc. (Nasdaq: CODX) (the “Company”), a molecular diagnostics company with a uniq...
Co-Diagnostics (NASDAQ: CODX ): Q3 GAAP EPS of -$0.10 misses by $0.04 . Revenue of $0.04M (+300.0% Y/Y) misses by $0.78M . Press Release More news on: Co-Diagnostics, Inc., Earnings news and commentary, Healthcare stocks news, ,
Revenue includes sales of infectious disease, mosquito abatement products and AgBio primer design services Co-Diagnostics, Inc. (Nasdaq: CODX) , a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today the fi...
New York, Oct. 31, 2019 (GLOBE NEWSWIRE) -- H.C. Wainwright has reiterated their “Buy” rating for Co-Diagnostics, Inc. (Nasdaq: CODX) , a biotech with a patented platform for the development of molecular diagnostic tests, following news that the company continues to execute o...
Salt Lake City, Oct. 29, 2019 (GLOBE NEWSWIRE) -- Salt Lake City, Utah – October 29, 2019 – Co-Diagnostics, Inc. (Nasdaq: CODX) (the “Company”), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests...
Vector Smart™ products being presented at 6 vector control conferences in October to prepare for 2020 mosquito season Co-Diagnostics, Inc. (Nasdaq: CODX) , a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, anno...
Salt Lake City, Oct. 10, 2019 (GLOBE NEWSWIRE) -- Co-Diagnostics, Inc. (Nasdaq: CODX) , a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today the product launch of their Vector Smart™ ZDC test, used to ide...
Salt Lake City, UT, Oct. 03, 2019 (GLOBE NEWSWIRE) -- Co-Diagnostics, Inc. (Nasdaq: CODX) , a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today that it will be presenting liquid biopsy applications of its paten...
News, Short Squeeze, Breakout and More Instantly...
Co-Diagnostics, Inc. Announces First Quarter 2024 Earnings Release Date and Webcast PR Newswire SALT LAKE CITY , April 25, 2024 /PRNewswire/ -- Co-Diagnostics, Inc. (NASDAQ: CODX), a molecular diagnostics company with a unique, patented platform for the developme...
Co-Diagnostics, Inc. to Host Booth and Deliver Presentation at APRC 2024 in Taiwan PR Newswire SALT LAKE CITY , April 24, 2024 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq: CODX) (the "Company" or "Co-Dx"), a molecular diagnostics company with a unique, pate...
Co-Diagnostics, Inc. Inaugurates New Manufacturing Facility in Utah with Ribbon Cutting Event PR Newswire Ribbon-cutting included support from Mayor Wood of South Salt Lake and other dignitaries SALT LAKE CITY , April 12, 2024 /PRNewswire/ -- ...